What is the equity of Incyte this year?
Incyte has equity of 5.19 B USD this year.
Incyte Equity 2024
Incyte Equity
5.19 B USD
Ticker
INCY
ISIN
US45337C1027
WKN
896133
In 2024, Incyte's equity was 5.19 B USD, a 18.76% increase from the 4.37 B USD equity in the previous year.
Incyte Aktienanalyse
What does Incyte do?
The Incyte Corporation is a global biotechnology company specializing in the research and development of drugs for the treatment of cancer and other serious diseases. Incyte was founded in 1991 in Delaware, USA, by Roy Whitfield, a biotech entrepreneur, with the aim of finding new approaches to drug discovery. The company initially focused on developing DNA sequencing technologies and building an extensive database for drug identification. Over the years, Incyte expanded its expertise in genomics research and collaborated with pharmaceutical companies to develop new medications. In 2002, Incyte entered into a strategic alliance with Eli Lilly and Company to jointly research drugs for cancer and other diseases. Today, Incyte offers a wide range of medications for the treatment of cancer, immune and inflammatory disorders, and rare genetic diseases. The company's business model is based on the discovery and development of new drugs, utilizing its strengths in genomics research and biomarker development to identify and develop targeted therapies. Incyte has also increasingly focused on the development of immunotherapies, particularly antibodies targeting cancer and other diseases by activating the immune system. The company has positioned itself as a leading provider of genetic tests for rare diseases in the United States, offering a broad range of diagnostic tests based on genetic mutations. Incyte is a rapidly growing company with a strong emphasis on innovation and research. It has a strong presence in the field of cancer therapy and is working to expand its expertise in immunology and genomics research. Incyte is considered a promising candidate for future growth and success in drug development in the biotech industry. Incyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.Incyte revenue by segment
82 % Product
14 % Product Royalty
4 % Milestone & Contract
Equity Details
Analyzing Incyte's Equity
Incyte's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Incyte's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Incyte's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Incyte's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Incyte’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Incyte stock
What was the equity of Incyte compared to the previous year?
The equity of Incyte has increased/decreased by 18.76% increased compared to the previous year.
What impact does a high equity have on investors of Incyte?
A high equity is advantageous for investors of Incyte as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Incyte?
A low equity can be a risk for investors of Incyte, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Incyte affect the company?
An increase in equity of Incyte can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Incyte affect the company?
A reduction in equity of Incyte can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Incyte?
Some factors that can affect the equity of Incyte include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Incyte so important for investors?
The equity of Incyte is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Incyte take to change the equity?
To change equity, Incyte can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Incyte pay?
Over the past 12 months, Incyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Incyte is expected to pay a dividend of 0 USD.
What is the dividend yield of Incyte?
The current dividend yield of Incyte is .
When does Incyte pay dividends?
Incyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Incyte?
Incyte paid dividends every year for the past 0 years.
What is the dividend of Incyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Incyte located?
Incyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von Incyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Incyte from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.
When did Incyte pay the last dividend?
The last dividend was paid out on 12/18/2024.
What was the dividend of Incyte in the year 2023?
In the year 2023, Incyte distributed 0 USD as dividends.
In which currency does Incyte pay out the dividend?
The dividends of Incyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The Incyte stock can be added to a savings plan with the following providers: Trade Republic and Consorsbank
Andere Kennzahlen von Incyte
Our stock analysis for Incyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Incyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
